ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome…

HOUSTON, Dec. 11, 2024 /PRNewswire/ – Omnira Software™, one of the fastest-growing providers of planning, reserves management, and data insights solutions, is pleased to announce a strategic partnership with PDQ Decisions™, a portfolio optimization expert and reserves management solutions…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.